nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—polycystic ovary syndrome	0.65	1	CbGaD
Mesalazine—PTGS2—ovarian follicle—polycystic ovary syndrome	0.00904	0.11	CbGeAlD
Mesalazine—IKBKB—embryo—polycystic ovary syndrome	0.00384	0.0466	CbGeAlD
Mesalazine—CHUK—adipose tissue—polycystic ovary syndrome	0.00373	0.0452	CbGeAlD
Mesalazine—CHUK—adrenal gland—polycystic ovary syndrome	0.00334	0.0406	CbGeAlD
Mesalazine—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00332	0.0484	CcSEcCtD
Mesalazine—CHUK—female gonad—polycystic ovary syndrome	0.00312	0.0378	CbGeAlD
Mesalazine—CHUK—endocrine gland—polycystic ovary syndrome	0.0029	0.0352	CbGeAlD
Mesalazine—IKBKB—endometrium—polycystic ovary syndrome	0.00281	0.0341	CbGeAlD
Mesalazine—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.00269	0.0392	CcSEcCtD
Mesalazine—IKBKB—uterus—polycystic ovary syndrome	0.00259	0.0314	CbGeAlD
Mesalazine—IKBKB—pituitary gland—polycystic ovary syndrome	0.00254	0.0309	CbGeAlD
Mesalazine—IKBKB—adipose tissue—polycystic ovary syndrome	0.00253	0.0307	CbGeAlD
Mesalazine—Nail disorder—Metformin—polycystic ovary syndrome	0.00244	0.0356	CcSEcCtD
Mesalazine—Upset stomach—Metformin—polycystic ovary syndrome	0.00241	0.0352	CcSEcCtD
Mesalazine—PPARG—embryo—polycystic ovary syndrome	0.00239	0.029	CbGeAlD
Mesalazine—IKBKB—adrenal gland—polycystic ovary syndrome	0.00227	0.0276	CbGeAlD
Mesalazine—IKBKB—female gonad—polycystic ovary syndrome	0.00212	0.0257	CbGeAlD
Mesalazine—IKBKB—vagina—polycystic ovary syndrome	0.00211	0.0255	CbGeAlD
Mesalazine—ALOX5—adipose tissue—polycystic ovary syndrome	0.0021	0.0255	CbGeAlD
Mesalazine—Salicylic acid—AKR1C1—polycystic ovary syndrome	0.00199	0.275	CrCbGaD
Mesalazine—IKBKB—endocrine gland—polycystic ovary syndrome	0.00197	0.0239	CbGeAlD
Mesalazine—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00195	0.0285	CcSEcCtD
Mesalazine—Blood disorder—Metformin—polycystic ovary syndrome	0.00189	0.0276	CcSEcCtD
Mesalazine—ALOX5—adrenal gland—polycystic ovary syndrome	0.00188	0.0228	CbGeAlD
Mesalazine—MPO—pituitary gland—polycystic ovary syndrome	0.00178	0.0216	CbGeAlD
Mesalazine—ALOX5—female gonad—polycystic ovary syndrome	0.00176	0.0213	CbGeAlD
Mesalazine—ALOX5—endocrine gland—polycystic ovary syndrome	0.00163	0.0198	CbGeAlD
Mesalazine—PPARG—uterus—polycystic ovary syndrome	0.00161	0.0196	CbGeAlD
Mesalazine—MPO—adrenal gland—polycystic ovary syndrome	0.00159	0.0193	CbGeAlD
Mesalazine—PPARG—adipose tissue—polycystic ovary syndrome	0.00158	0.0191	CbGeAlD
Mesalazine—Neuropathy—Metformin—polycystic ovary syndrome	0.00148	0.0217	CcSEcCtD
Mesalazine—PPARG—adrenal gland—polycystic ovary syndrome	0.00141	0.0172	CbGeAlD
Mesalazine—MPO—endocrine gland—polycystic ovary syndrome	0.00138	0.0168	CbGeAlD
Mesalazine—Ear pain—Metformin—polycystic ovary syndrome	0.00134	0.0196	CcSEcCtD
Mesalazine—PPARG—female gonad—polycystic ovary syndrome	0.00132	0.016	CbGeAlD
Mesalazine—PPARG—vagina—polycystic ovary syndrome	0.00131	0.0159	CbGeAlD
Mesalazine—PPARG—endocrine gland—polycystic ovary syndrome	0.00123	0.0149	CbGeAlD
Mesalazine—PTGS2—embryo—polycystic ovary syndrome	0.00122	0.0148	CbGeAlD
Mesalazine—Renal impairment—Metformin—polycystic ovary syndrome	0.00121	0.0176	CcSEcCtD
Mesalazine—Droxidopa—ADRA1D—polycystic ovary syndrome	0.00118	0.163	CrCbGaD
Mesalazine—Lethargy—Metformin—polycystic ovary syndrome	0.00117	0.0171	CcSEcCtD
Mesalazine—Migraine—Metformin—polycystic ovary syndrome	0.00113	0.0165	CcSEcCtD
Mesalazine—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00106	0.0155	CcSEcCtD
Mesalazine—Droxidopa—ADRB3—polycystic ovary syndrome	0.00106	0.146	CrCbGaD
Mesalazine—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00105	0.0153	CcSEcCtD
Mesalazine—Breast disorder—Metformin—polycystic ovary syndrome	0.00104	0.0151	CcSEcCtD
Mesalazine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00103	0.0151	CcSEcCtD
Mesalazine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00103	0.015	CcSEcCtD
Mesalazine—Droxidopa—ADRA1B—polycystic ovary syndrome	0.001	0.139	CrCbGaD
Mesalazine—PTGS2—adrenal cortex—polycystic ovary syndrome	0.001	0.0121	CbGeAlD
Mesalazine—Abdominal distension—Metformin—polycystic ovary syndrome	0.000998	0.0146	CcSEcCtD
Mesalazine—Influenza—Metformin—polycystic ovary syndrome	0.000992	0.0145	CcSEcCtD
Mesalazine—Pancreatitis—Metformin—polycystic ovary syndrome	0.000972	0.0142	CcSEcCtD
Mesalazine—Angina pectoris—Metformin—polycystic ovary syndrome	0.000966	0.0141	CcSEcCtD
Mesalazine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000951	0.0139	CcSEcCtD
Mesalazine—PTGS1—endometrium—polycystic ovary syndrome	0.000936	0.0113	CbGeAlD
Mesalazine—Neutropenia—Metformin—polycystic ovary syndrome	0.000927	0.0135	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000922	0.0134	CcSEcCtD
Mesalazine—Olsalazine—PPARG—polycystic ovary syndrome	0.000917	0.127	CrCbGaD
Mesalazine—PTGS2—endometrium—polycystic ovary syndrome	0.000894	0.0108	CbGeAlD
Mesalazine—Infestation—Metformin—polycystic ovary syndrome	0.000884	0.0129	CcSEcCtD
Mesalazine—Infestation NOS—Metformin—polycystic ovary syndrome	0.000884	0.0129	CcSEcCtD
Mesalazine—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000867	0.0126	CcSEcCtD
Mesalazine—PTGS1—uterus—polycystic ovary syndrome	0.000862	0.0105	CbGeAlD
Mesalazine—PTGS1—pituitary gland—polycystic ovary syndrome	0.000847	0.0103	CbGeAlD
Mesalazine—PTGS1—adipose tissue—polycystic ovary syndrome	0.000843	0.0102	CbGeAlD
Mesalazine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000836	0.0122	CcSEcCtD
Mesalazine—PTGS2—uterus—polycystic ovary syndrome	0.000824	0.00999	CbGeAlD
Mesalazine—PTGS2—pituitary gland—polycystic ovary syndrome	0.000809	0.00981	CbGeAlD
Mesalazine—PTGS2—adipose tissue—polycystic ovary syndrome	0.000806	0.00977	CbGeAlD
Mesalazine—Rhinitis—Metformin—polycystic ovary syndrome	0.000796	0.0116	CcSEcCtD
Mesalazine—Hepatitis—Metformin—polycystic ovary syndrome	0.000794	0.0116	CcSEcCtD
Mesalazine—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000782	0.0114	CcSEcCtD
Mesalazine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00078	0.0114	CcSEcCtD
Mesalazine—PTGS1—adrenal gland—polycystic ovary syndrome	0.000756	0.00917	CbGeAlD
Mesalazine—Eye disorder—Metformin—polycystic ovary syndrome	0.000742	0.0108	CcSEcCtD
Mesalazine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000737	0.0107	CcSEcCtD
Mesalazine—PTGS2—adrenal gland—polycystic ovary syndrome	0.000723	0.00877	CbGeAlD
Mesalazine—Angiopathy—Metformin—polycystic ovary syndrome	0.00072	0.0105	CcSEcCtD
Mesalazine—Immune system disorder—Metformin—polycystic ovary syndrome	0.000717	0.0105	CcSEcCtD
Mesalazine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000715	0.0104	CcSEcCtD
Mesalazine—Chills—Metformin—polycystic ovary syndrome	0.000712	0.0104	CcSEcCtD
Mesalazine—PTGS1—female gonad—polycystic ovary syndrome	0.000705	0.00855	CbGeAlD
Mesalazine—PTGS1—vagina—polycystic ovary syndrome	0.000701	0.0085	CbGeAlD
Mesalazine—Erythema—Metformin—polycystic ovary syndrome	0.000691	0.0101	CcSEcCtD
Mesalazine—Flatulence—Metformin—polycystic ovary syndrome	0.000681	0.00994	CcSEcCtD
Mesalazine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000677	0.00987	CcSEcCtD
Mesalazine—Droxidopa—ADRA1A—polycystic ovary syndrome	0.000676	0.0936	CrCbGaD
Mesalazine—PTGS2—female gonad—polycystic ovary syndrome	0.000674	0.00817	CbGeAlD
Mesalazine—PTGS2—vagina—polycystic ovary syndrome	0.00067	0.00812	CbGeAlD
Mesalazine—Muscle spasms—Metformin—polycystic ovary syndrome	0.000664	0.00969	CcSEcCtD
Mesalazine—PTGS1—endocrine gland—polycystic ovary syndrome	0.000656	0.00795	CbGeAlD
Mesalazine—Vision blurred—Metformin—polycystic ovary syndrome	0.000651	0.0095	CcSEcCtD
Mesalazine—Tremor—Metformin—polycystic ovary syndrome	0.000647	0.00945	CcSEcCtD
Mesalazine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000641	0.00935	CcSEcCtD
Mesalazine—PTGS2—endocrine gland—polycystic ovary syndrome	0.000627	0.0076	CbGeAlD
Mesalazine—Malaise—Metformin—polycystic ovary syndrome	0.000623	0.00909	CcSEcCtD
Mesalazine—Syncope—Metformin—polycystic ovary syndrome	0.00062	0.00904	CcSEcCtD
Mesalazine—Palpitations—Metformin—polycystic ovary syndrome	0.000611	0.00891	CcSEcCtD
Mesalazine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000607	0.00886	CcSEcCtD
Mesalazine—Hypertension—Metformin—polycystic ovary syndrome	0.000597	0.0087	CcSEcCtD
Mesalazine—Chest pain—Metformin—polycystic ovary syndrome	0.000588	0.00858	CcSEcCtD
Mesalazine—Myalgia—Metformin—polycystic ovary syndrome	0.000588	0.00858	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000584	0.00852	CcSEcCtD
Mesalazine—Discomfort—Metformin—polycystic ovary syndrome	0.000581	0.00848	CcSEcCtD
Mesalazine—Oedema—Metformin—polycystic ovary syndrome	0.000564	0.00823	CcSEcCtD
Mesalazine—Infection—Metformin—polycystic ovary syndrome	0.00056	0.00817	CcSEcCtD
Mesalazine—Shock—Metformin—polycystic ovary syndrome	0.000555	0.0081	CcSEcCtD
Mesalazine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000553	0.00807	CcSEcCtD
Mesalazine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000552	0.00806	CcSEcCtD
Mesalazine—Skin disorder—Metformin—polycystic ovary syndrome	0.000548	0.00799	CcSEcCtD
Mesalazine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000545	0.00795	CcSEcCtD
Mesalazine—Anorexia—Metformin—polycystic ovary syndrome	0.000538	0.00784	CcSEcCtD
Mesalazine—Hypotension—Metformin—polycystic ovary syndrome	0.000527	0.00769	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000514	0.0075	CcSEcCtD
Mesalazine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000506	0.00739	CcSEcCtD
Mesalazine—Dyspnoea—Metformin—polycystic ovary syndrome	0.000503	0.00734	CcSEcCtD
Mesalazine—Somnolence—Metformin—polycystic ovary syndrome	0.000501	0.00732	CcSEcCtD
Mesalazine—Dyspepsia—Metformin—polycystic ovary syndrome	0.000496	0.00724	CcSEcCtD
Mesalazine—Decreased appetite—Metformin—polycystic ovary syndrome	0.00049	0.00715	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000487	0.0071	CcSEcCtD
Mesalazine—Fatigue—Metformin—polycystic ovary syndrome	0.000486	0.00709	CcSEcCtD
Mesalazine—Constipation—Metformin—polycystic ovary syndrome	0.000482	0.00704	CcSEcCtD
Mesalazine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000465	0.00678	CcSEcCtD
Mesalazine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000461	0.00673	CcSEcCtD
Mesalazine—Urticaria—Metformin—polycystic ovary syndrome	0.000448	0.00654	CcSEcCtD
Mesalazine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000446	0.0065	CcSEcCtD
Mesalazine—Asthenia—Metformin—polycystic ovary syndrome	0.000405	0.0059	CcSEcCtD
Mesalazine—Droxidopa—ADRB2—polycystic ovary syndrome	0.000402	0.0557	CrCbGaD
Mesalazine—Pruritus—Metformin—polycystic ovary syndrome	0.000399	0.00582	CcSEcCtD
Mesalazine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000386	0.00563	CcSEcCtD
Mesalazine—Dizziness—Metformin—polycystic ovary syndrome	0.000373	0.00544	CcSEcCtD
Mesalazine—Vomiting—Metformin—polycystic ovary syndrome	0.000359	0.00523	CcSEcCtD
Mesalazine—Rash—Metformin—polycystic ovary syndrome	0.000356	0.00519	CcSEcCtD
Mesalazine—Dermatitis—Metformin—polycystic ovary syndrome	0.000355	0.00518	CcSEcCtD
Mesalazine—Headache—Metformin—polycystic ovary syndrome	0.000353	0.00515	CcSEcCtD
Mesalazine—Nausea—Metformin—polycystic ovary syndrome	0.000335	0.00489	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.71e-05	0.000194	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT2—polycystic ovary syndrome	3.71e-05	0.000193	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	3.7e-05	0.000193	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GNAS—polycystic ovary syndrome	3.68e-05	0.000192	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FSHR—polycystic ovary syndrome	3.68e-05	0.000192	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKR1C3—polycystic ovary syndrome	3.67e-05	0.000192	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—YAP1—polycystic ovary syndrome	3.65e-05	0.000191	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—IRS2—polycystic ovary syndrome	3.65e-05	0.00019	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMMR—polycystic ovary syndrome	3.62e-05	0.000189	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RPL37A—polycystic ovary syndrome	3.62e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FST—polycystic ovary syndrome	3.61e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Disease—TNRC6B—polycystic ovary syndrome	3.61e-05	0.000189	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CAMK2D—polycystic ovary syndrome	3.61e-05	0.000188	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	3.57e-05	0.000187	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—IL6—polycystic ovary syndrome	3.57e-05	0.000187	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—IL6—polycystic ovary syndrome	3.57e-05	0.000187	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.57e-05	0.000186	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PNPLA2—polycystic ovary syndrome	3.56e-05	0.000186	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TNRC6B—polycystic ovary syndrome	3.55e-05	0.000185	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—IL6—polycystic ovary syndrome	3.54e-05	0.000185	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LHB—polycystic ovary syndrome	3.53e-05	0.000184	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NAMPT—polycystic ovary syndrome	3.51e-05	0.000183	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—IL6—polycystic ovary syndrome	3.51e-05	0.000183	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—NCOR1—polycystic ovary syndrome	3.5e-05	0.000183	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—IL6—polycystic ovary syndrome	3.5e-05	0.000182	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP11A1—polycystic ovary syndrome	3.47e-05	0.000181	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.46e-05	0.00018	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HSD3B1—polycystic ovary syndrome	3.45e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.45e-05	0.00018	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IRS2—polycystic ovary syndrome	3.45e-05	0.00018	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CRP—polycystic ovary syndrome	3.45e-05	0.00018	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.44e-05	0.00018	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—IL6—polycystic ovary syndrome	3.44e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ATF1—polycystic ovary syndrome	3.44e-05	0.000179	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HMMR—polycystic ovary syndrome	3.43e-05	0.000179	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.41e-05	0.000178	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SRD5A1—polycystic ovary syndrome	3.38e-05	0.000176	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.36e-05	0.000175	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.34e-05	0.000174	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CYP1A1—polycystic ovary syndrome	3.32e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IRS1—polycystic ovary syndrome	3.32e-05	0.000173	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—IRS2—polycystic ovary syndrome	3.31e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SCT—polycystic ovary syndrome	3.31e-05	0.000172	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FST—polycystic ovary syndrome	3.28e-05	0.000171	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKR1C3—polycystic ovary syndrome	3.27e-05	0.000171	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	3.24e-05	0.000169	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.24e-05	0.000169	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	3.23e-05	0.000169	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP17A1—polycystic ovary syndrome	3.22e-05	0.000168	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STAR—polycystic ovary syndrome	3.22e-05	0.000168	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LHB—polycystic ovary syndrome	3.2e-05	0.000167	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AR—polycystic ovary syndrome	3.19e-05	0.000167	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—IRS1—polycystic ovary syndrome	3.19e-05	0.000166	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	3.19e-05	0.000166	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TAB1—polycystic ovary syndrome	3.17e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	3.17e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.15e-05	0.000165	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—LHB—polycystic ovary syndrome	3.15e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PRL—polycystic ovary syndrome	3.14e-05	0.000164	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.13e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ATF1—polycystic ovary syndrome	3.12e-05	0.000163	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGF18—polycystic ovary syndrome	3.1e-05	0.000162	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—MTHFR—polycystic ovary syndrome	3.1e-05	0.000162	CbGpPWpGaD
Mesalazine—CHUK—Disease—TCF7L2—polycystic ovary syndrome	3.09e-05	0.000161	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HSD3B2—polycystic ovary syndrome	3.08e-05	0.000161	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RBP4—polycystic ovary syndrome	3.07e-05	0.00016	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT2—polycystic ovary syndrome	3.07e-05	0.00016	CbGpPWpGaD
Mesalazine—CHUK—Disease—SLC2A4—polycystic ovary syndrome	3.04e-05	0.000159	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.03e-05	0.000158	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IRS1—polycystic ovary syndrome	3.01e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SCT—polycystic ovary syndrome	3e-05	0.000156	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKR1C1—polycystic ovary syndrome	2.98e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT2—polycystic ovary syndrome	2.95e-05	0.000154	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL6—polycystic ovary syndrome	2.93e-05	0.000153	CbGpPWpGaD
Mesalazine—CHUK—Disease—PRL—polycystic ovary syndrome	2.9e-05	0.000151	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—IRS1—polycystic ovary syndrome	2.89e-05	0.000151	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	2.88e-05	0.00015	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TAB1—polycystic ovary syndrome	2.88e-05	0.00015	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMMR—polycystic ovary syndrome	2.87e-05	0.00015	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—YAP1—polycystic ovary syndrome	2.87e-05	0.00015	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.86e-05	0.000149	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PRL—polycystic ovary syndrome	2.85e-05	0.000149	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GAB1—polycystic ovary syndrome	2.83e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKR1C1—polycystic ovary syndrome	2.82e-05	0.000147	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGF18—polycystic ovary syndrome	2.81e-05	0.000147	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NCOR1—polycystic ovary syndrome	2.79e-05	0.000146	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TH—polycystic ovary syndrome	2.79e-05	0.000146	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RBP4—polycystic ovary syndrome	2.79e-05	0.000145	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT2—polycystic ovary syndrome	2.79e-05	0.000145	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SULT2A1—polycystic ovary syndrome	2.74e-05	0.000143	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HSD3B1—polycystic ovary syndrome	2.74e-05	0.000143	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—SLC2A4—polycystic ovary syndrome	2.71e-05	0.000142	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.71e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—INSR—polycystic ovary syndrome	2.71e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—BCL2—polycystic ovary syndrome	2.68e-05	0.00014	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT2—polycystic ovary syndrome	2.68e-05	0.00014	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RRM2—polycystic ovary syndrome	2.66e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL18—polycystic ovary syndrome	2.64e-05	0.000138	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGF18—polycystic ovary syndrome	2.62e-05	0.000137	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—YAP1—polycystic ovary syndrome	2.6e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RBP4—polycystic ovary syndrome	2.6e-05	0.000136	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRG1—polycystic ovary syndrome	2.59e-05	0.000135	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NR3C1—polycystic ovary syndrome	2.58e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.57e-05	0.000134	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.57e-05	0.000134	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GAB1—polycystic ovary syndrome	2.57e-05	0.000134	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—YAP1—polycystic ovary syndrome	2.56e-05	0.000134	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP19A1—polycystic ovary syndrome	2.55e-05	0.000133	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.53e-05	0.000132	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PPARG—polycystic ovary syndrome	2.51e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PGR—polycystic ovary syndrome	2.51e-05	0.000131	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LHB—polycystic ovary syndrome	2.5e-05	0.00013	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—POMC—polycystic ovary syndrome	2.48e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	2.48e-05	0.000129	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—INS—polycystic ovary syndrome	2.46e-05	0.000129	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NAMPT—polycystic ovary syndrome	2.46e-05	0.000128	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—INSR—polycystic ovary syndrome	2.45e-05	0.000128	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.45e-05	0.000128	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HSD3B2—polycystic ovary syndrome	2.44e-05	0.000127	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—IL6—polycystic ovary syndrome	2.44e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—BCL2—polycystic ovary syndrome	2.43e-05	0.000127	CbGpPWpGaD
Mesalazine—CHUK—Disease—NCOR1—polycystic ovary syndrome	2.43e-05	0.000127	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP11A1—polycystic ovary syndrome	2.43e-05	0.000127	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—polycystic ovary syndrome	2.42e-05	0.000126	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.41e-05	0.000126	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL18—polycystic ovary syndrome	2.4e-05	0.000125	CbGpPWpGaD
Mesalazine—PTGS2—Disease—GAB1—polycystic ovary syndrome	2.39e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRG1—polycystic ovary syndrome	2.39e-05	0.000125	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1C1—polycystic ovary syndrome	2.37e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRG1—polycystic ovary syndrome	2.34e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NAMPT—polycystic ovary syndrome	2.33e-05	0.000122	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.33e-05	0.000122	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GHRL—polycystic ovary syndrome	2.33e-05	0.000122	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PLAT—polycystic ovary syndrome	2.33e-05	0.000122	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.29e-05	0.00012	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKR1C3—polycystic ovary syndrome	2.29e-05	0.00012	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GNAS—polycystic ovary syndrome	2.28e-05	0.000119	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PGR—polycystic ovary syndrome	2.27e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP17A1—polycystic ovary syndrome	2.26e-05	0.000118	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	2.25e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ATF1—polycystic ovary syndrome	2.22e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IRS2—polycystic ovary syndrome	2.21e-05	0.000116	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CRP—polycystic ovary syndrome	2.21e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—polycystic ovary syndrome	2.21e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SULT2A1—polycystic ovary syndrome	2.18e-05	0.000114	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKR1C3—polycystic ovary syndrome	2.17e-05	0.000113	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NCOR1—polycystic ovary syndrome	2.17e-05	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.17e-05	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—polycystic ovary syndrome	2.15e-05	0.000112	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TNRC6B—polycystic ovary syndrome	2.14e-05	0.000112	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLAT—polycystic ovary syndrome	2.11e-05	0.00011	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GHRL—polycystic ovary syndrome	2.11e-05	0.00011	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RRM2—polycystic ovary syndrome	2.11e-05	0.00011	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP1A1—polycystic ovary syndrome	2.06e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NGFR—polycystic ovary syndrome	2.05e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS2—polycystic ovary syndrome	2.04e-05	0.000107	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—YAP1—polycystic ovary syndrome	2.03e-05	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRL—polycystic ovary syndrome	2.03e-05	0.000106	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ATF1—polycystic ovary syndrome	2.01e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS2—polycystic ovary syndrome	2.01e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CRP—polycystic ovary syndrome	2.01e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.96e-05	0.000103	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TH—polycystic ovary syndrome	1.95e-05	0.000102	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NAMPT—polycystic ovary syndrome	1.95e-05	0.000102	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.94e-05	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IRS1—polycystic ovary syndrome	1.93e-05	0.000101	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP11A1—polycystic ovary syndrome	1.93e-05	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.93e-05	0.000101	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—polycystic ovary syndrome	1.92e-05	0.0001	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.91e-05	9.99e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC2A4—polycystic ovary syndrome	1.9e-05	9.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NGFR—polycystic ovary syndrome	1.86e-05	9.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRL—polycystic ovary syndrome	1.84e-05	9.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TCF7L2—polycystic ovary syndrome	1.83e-05	9.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1C3—polycystic ovary syndrome	1.82e-05	9.5e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A4—polycystic ovary syndrome	1.8e-05	9.4e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SERPINE1—polycystic ovary syndrome	1.8e-05	9.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP17A1—polycystic ovary syndrome	1.79e-05	9.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT2—polycystic ovary syndrome	1.79e-05	9.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNAS—polycystic ovary syndrome	1.79e-05	9.33e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP19A1—polycystic ovary syndrome	1.79e-05	9.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS1—polycystic ovary syndrome	1.78e-05	9.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS1—polycystic ovary syndrome	1.75e-05	9.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.75e-05	9.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRL—polycystic ovary syndrome	1.72e-05	8.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—INS—polycystic ovary syndrome	1.71e-05	8.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.7e-05	8.88e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—polycystic ovary syndrome	1.68e-05	8.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRG1—polycystic ovary syndrome	1.67e-05	8.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT2—polycystic ovary syndrome	1.65e-05	8.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT2—polycystic ovary syndrome	1.62e-05	8.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNAS—polycystic ovary syndrome	1.62e-05	8.46e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNAS—polycystic ovary syndrome	1.6e-05	8.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SERPINE1—polycystic ovary syndrome	1.57e-05	8.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—polycystic ovary syndrome	1.56e-05	8.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TH—polycystic ovary syndrome	1.55e-05	8.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.54e-05	8.06e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—polycystic ovary syndrome	1.53e-05	8e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—INS—polycystic ovary syndrome	1.52e-05	7.96e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NCOR1—polycystic ovary syndrome	1.52e-05	7.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRG1—polycystic ovary syndrome	1.52e-05	7.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A4—polycystic ovary syndrome	1.51e-05	7.87e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1A1—polycystic ovary syndrome	1.44e-05	7.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NCOR1—polycystic ovary syndrome	1.44e-05	7.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS2—polycystic ovary syndrome	1.43e-05	7.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP19A1—polycystic ovary syndrome	1.42e-05	7.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—polycystic ovary syndrome	1.42e-05	7.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRG1—polycystic ovary syndrome	1.41e-05	7.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—polycystic ovary syndrome	1.4e-05	7.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—polycystic ovary syndrome	1.39e-05	7.25e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—polycystic ovary syndrome	1.34e-05	7.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS2—polycystic ovary syndrome	1.3e-05	6.77e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—polycystic ovary syndrome	1.27e-05	6.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—polycystic ovary syndrome	1.27e-05	6.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNAS—polycystic ovary syndrome	1.27e-05	6.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—polycystic ovary syndrome	1.26e-05	6.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS1—polycystic ovary syndrome	1.25e-05	6.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS2—polycystic ovary syndrome	1.21e-05	6.32e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOR1—polycystic ovary syndrome	1.21e-05	6.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—polycystic ovary syndrome	1.2e-05	6.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—INS—polycystic ovary syndrome	1.2e-05	6.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—polycystic ovary syndrome	1.16e-05	6.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT2—polycystic ovary syndrome	1.16e-05	6.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A1—polycystic ovary syndrome	1.14e-05	5.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS1—polycystic ovary syndrome	1.13e-05	5.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.1e-05	5.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—polycystic ovary syndrome	1.09e-05	5.69e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—polycystic ovary syndrome	1.09e-05	5.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—INS—polycystic ovary syndrome	1.09e-05	5.66e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—polycystic ovary syndrome	1.07e-05	5.6e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—INS—polycystic ovary syndrome	1.07e-05	5.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—polycystic ovary syndrome	1.07e-05	5.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS1—polycystic ovary syndrome	1.06e-05	5.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—polycystic ovary syndrome	1.05e-05	5.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT2—polycystic ovary syndrome	1.05e-05	5.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—INS—polycystic ovary syndrome	1.01e-05	5.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.97e-06	5.2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT2—polycystic ovary syndrome	9.79e-06	5.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—polycystic ovary syndrome	9.3e-06	4.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—polycystic ovary syndrome	8.65e-06	4.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—polycystic ovary syndrome	8.53e-06	4.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—INS—polycystic ovary syndrome	8.48e-06	4.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—polycystic ovary syndrome	8.09e-06	4.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.56e-06	3.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—polycystic ovary syndrome	7.47e-06	3.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—polycystic ovary syndrome	7.34e-06	3.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.86e-06	3.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—polycystic ovary syndrome	5.23e-06	2.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—polycystic ovary syndrome	4.74e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—polycystic ovary syndrome	4.42e-06	2.31e-05	CbGpPWpGaD
